Dr. Jitendra Singh inaugurates RSSDI Annual Conference in Bengaluru
Synopsis
Key Takeaways
India's diabetes research community assembled under one roof on Friday, 20 November 2026, as Union Science and Technology Minister Dr. Jitendra Singh arrived at Aldovia Resorts and Convention, Bengaluru, to inaugurate the four-day Annual Academic Conference of the Research Society for Study of Diabetes in India (RSSDI) — the country's largest body of diabetes scholars, researchers and practitioners.
Posting on X, Dr. Singh described being 'grateful for the affectionate welcome extended by esteemed colleagues from across the country' and expressed anticipation for 'meaningful discussions and interactions on advancing Diabetes research and healthcare.' The gathering draws endocrinologists, clinicians and biomedical researchers from every corner of India to a single platform where laboratory findings meet clinical practice and, ultimately, national health policy.
Why RSSDI's Annual Meeting Carries Outsized Policy Weight
India carries one of the world's heaviest diabetes burdens, with prevalence climbing steeply in both urban centres and rural districts. The RSSDI, as the premier professional society for diabetes science in the country, functions not just as an academic forum but as a feeder institution — translating conference research into clinical guidelines that cascade into government programmes.
The national architecture for tackling the disease stretches back to the National Programme for Prevention and Control of Cancer, Diabetes, Cardiovascular Diseases and Stroke (NPCDCS), launched in 2010. India's National Health Policy 2017 doubled down on the priority, calling for sharper research, strengthened surveillance and more affordable care delivery. RSSDI gatherings have historically fed directly into those policy pipelines.
A Science Minister at a Medical Forum — The Significance of the Presence
Dr. Singh's portfolio spans Science and Technology, Earth Sciences, and oversight of key research bodies — making his appearance at a medical-research conference more than ceremonial. His ministry's agencies, including the Department of Biotechnology (DBT) and the Indian Council of Medical Research (ICMR), are central to funding and directing diabetes science in India. A minister's presence at such a forum signals that the science establishment is watching conference outputs for potential integration into national programmes, including Ayushman Bharat.
Bengaluru, Karnataka's capital and India's foremost hub for biotechnology and healthcare research, is a fitting venue — the city's dense cluster of research institutions and pharmaceutical players makes it a natural crucible for translating academic debate into scalable health solutions.
Four days of deliberation begin now. The question the diabetes community will want answered: which recommendations make it out of the conference hall and into the corridors of North Block.